Trials / Terminated
TerminatedNCT00113048
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I study will involve escalating doses of CAMPATH until the goal dose for the cohort is tolerated. The CAMPATH goal dose will be administered to the patient subcutaneously (SQ) 3 times per week for up to 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAMPATH (alemtuzumab) |
Timeline
- Start date
- 2003-12-01
- Completion
- 2005-09-01
- First posted
- 2005-06-06
- Last updated
- 2014-02-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00113048. Inclusion in this directory is not an endorsement.